marimastat has been researched along with carboplatin in 2 studies
| Studies (marimastat) | Trials (marimastat) | Recent Studies (post-2010) (marimastat) | Studies (carboplatin) | Trials (carboplatin) | Recent Studies (post-2010) (carboplatin) |
|---|---|---|---|---|---|
| 215 | 28 | 53 | 12,895 | 4,001 | 5,244 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Neijt, JP | 1 |
| Anderson, IC; Eder, JP; Goffin, JR; Johnson, BE; Lynch, TJ; Shapiro, GI; Shipp, M; Skarin, AT; Supko, JG | 1 |
1 review(s) available for marimastat and carboplatin
| Article | Year |
|---|---|
[Cytostatic treatment of ovarian carcinoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Hydroxamic Acids; Ovarian Neoplasms; Paclitaxel; Protease Inhibitors; Trastuzumab | 1999 |
1 trial(s) available for marimastat and carboplatin
| Article | Year |
|---|---|
Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Hematologic Diseases; Humans; Hydroxamic Acids; Infusions, Intravenous; Lung Neoplasms; Male; Metabolic Clearance Rate; Metalloendopeptidases; Middle Aged; Nausea; Paclitaxel; Treatment Outcome | 2005 |